
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Arvinas, Inc. - ARVN
The investigation concerns whether Arvinas and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On May 1, 2025, Arvinas issued a press release announcing that the Company and its development partners at Pfizer had“removed plans for a Phase 3 first-line combination trial with atirmociclib, as well as the planned Phase 3 second-line combination trial with a CDK4/6 inhibitor, from our joint development plan.” Arvinas's Chief Executive Officer said that the“decision was made following a review of the totality of emerging information, including external data results, the evolving treatment landscape in metastatic breast cancer, and long-term capital allocation.” Arvinas also“[a]nnounced a reduction in workforce of approximately one-third across the Company to streamline operations across the organization and enable the efficient progression of the Company's portfolio”, advising that“[t]he reduction is planned to be completed in the second quarter of 2025.”
On this news, Arvina's stock price fell $2.39 per share, or 24.84%, to close at $7.23 per share on May 1, 2025.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See .
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Danielle Peyton
Pomerantz LLP
...
646-581-9980 ext. 7980


Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research

- BTSE Celebrates Bitcoin Pizza Day 2025 With $5.22Mn Trading Competition And Community Giveaways
- GSR Leads $100M Private Placement Into Nasdaq-Listed Upexi, Inc. To Back Solana-Based Treasury Strategy
- Team Behind Popular Telegram Wallet Grindery Reveals Wallet Infra For AI Agents
- Bitget Launches PUNDIXUSDT Perpetual Futures And Enables Trading Bots
- New CFD Broker Versus Trade Launches With Unique 'Asset-Vs-Asset' Product Offering
- Common Launches First Privacy Web App With Subsecond Proving Times For Arbitrum And Aleph Zero EVM
Comments
No comment